Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 485

Sort by

Sort Order Select

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death

Ana Domostegui, Suresh Peddigari, Carol A. Mercer, Flavia Iannizzotto, Marta L. Rodriguez, Marta Garcia-Cajide, Virginia Amador, Sarah T. Diepstraten, Gemma L. Kelly, Ramón Salazar, Sara C. Kozma, Eric P. Kusnadi, Jian Kang, Antonio Gentilella, Richard B. Pearson, George Thomas, Joffrey Pelletier

Blood (2021) 137 (24): 3351–3364.

https://doi.org/10.1182/blood.2020007452

Published: 2021

Includes: Supplemental data

Journal Articles

Requirement for antiapoptotic MCL-1 during early erythropoiesis

Meghan E. Turnis, Ewa Kaminska, Kaitlyn H. Smith, Brittany J. Kartchner, Peter Vogel, Jonathan D. Laxton, Richard A. Ashmun, Paul A. Ney, Joseph T. Opferman

Blood (2021) 137 (14): 1945–1958.

https://doi.org/10.1182/blood.2020006916

Published: 2021

Includes: Supplemental data

Journal Articles

Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA)

Giovanni Del Poeta, MD, Annalisa Biagi, MD, Annalisa Chiarenza, MD PhD, Luca Laurenti, MD, Federico Pozzo, MSc, Idanna Innocenti, MD PhD, Riccardo Bomben, PhD, Maria Ilaria Del Principe, Enrico Santinelli, MD, Francesca Maria Rossi, PhD, Paolo de Fabritiis, MD, Maria Cantonetti, Antonella Zucchetto, William Arcese, Valter Gattei, MD

Blood (2019) 134 (Supplement_1): 1744.

https://doi.org/10.1182/blood-2019-122481

Published: 2019

Journal Articles

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, MD, Kiran Naqvi, MDMPH, Yesid Alvarado, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Elias Jabbour, MD, Gautam M. Borthakur, MD, Naveen Pemmaraju, MD, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Montalban Bravo, MD

Blood (2019) 134 (Supplement_1): 1726.

https://doi.org/10.1182/blood-2019-126005

Published: 2019

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Leo Meriranta, MD, Amjad Alkodsi, PhD, Annika Pasanen, MD PhD, Jari Haukka, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD Prof

Blood (2019) 134 (Supplement_1): 2781.

https://doi.org/10.1182/blood-2019-131220

Published: 2019

Journal Articles

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Claire N Harrison, Professor, Jacqueline S Garcia, MD, Ruben A Mesa, MD, Tim CP Somervaille, MD PhD, Rami S. Komrokji, MD, Naveen Pemmaraju, MD, Catriona Jamieson, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, James M. Foran, MD, Casey L. O'Connell, MD, Leanne Holes, BS, MBA,, Jia Jia, PhD MBA, Jason Harb, PhD, Jessica Hutti, PhD, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 671.

https://doi.org/10.1182/blood-2019-130158

Published: 2019

Journal Articles

CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma

Peiqi Zhao, Huilai Zhang, MD, Kai Fu, MD PhD, Xianhuo Wang, MD, Lanfang Li, Zhengzi Qian, Lihua Qiu, Shiyong Zhou

Blood (2019) 134 (Supplement_1): 4117.

https://doi.org/10.1182/blood-2019-127666

Published: 2019

Journal Articles

Does Venetoclax Cause Vitiligo?

Sujatha Baddam, MD, Jorge Diaz Castro, MD

Blood (2019) 134 (Supplement_1): 5139.

https://doi.org/10.1182/blood-2019-130854

Published: 2019

Journal Articles

All-Trans Retinoic Acid Enhances the Anti-Leukemia Effect of Venetoclax on Acute Myeloid Leukemia Cells

Dongbei Li, Sha Liu, Lin Chen, MD, Ruihua Fan, Cheng Cheng, Xudong Wei, PhD

Blood (2019) 134 (Supplement_1): 5055.

https://doi.org/10.1182/blood-2019-128551

Published: 2019

Journal Articles

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

Gregorio Campos-Cabrera, MD, Noe-Benjamin Vega-Tapia, MD, Virgina Campos-Cabrera, QFB EBC, Salvador Campos-Cabrera, MD, Jose-Luis Campos-Villagomez, MD, Esther Mendez-Garcia, MD

Blood (2019) 134 (Supplement_1): 5128.

https://doi.org/10.1182/blood-2019-127296

Published: 2019

Journal Articles

Mechanisms of Deregulation of Apoptosis in Myeloma

Simone Fulda, MD

Blood (2019) 134 (Supplement_1): SCI-10.

https://doi.org/10.1182/blood-2019-121102

Published: 2019

Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 2564.

https://doi.org/10.1182/blood-2019-131635

Published: 2019

Journal Articles

Functional profiling to improve therapy in TCL

Kojo S. J. Elenitoba-Johnson

Blood (2019) 133 (6): 504–506.

https://doi.org/10.1182/blood-2018-12-889741

Published: 2019

Journal Articles

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, Adam C. Palmer, Deborah Plana, Kay Shigemori, Sara N. Morrow, Alexandria Van Scoyk, Wenchao Wu, Elizabeth A. Brem, J. Paul Secrist, Lisa Drew, Alwin G. Schuller, Justin Cidado, Anthony Letai, David M. Weinstock

Blood (2019) 133 (6): 566–575.

https://doi.org/10.1182/blood-2018-07-865527

Published: 2019

Includes: Supplemental data

Journal Articles

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL

Kamil Bojarczuk, Kirsty Wienand, Jeremy A. Ryan, Linfeng Chen, Mariana Villalobos-Ortiz, Elisa Mandato, Joanna Stachura, Anthony Letai, Lee N. Lawton, Bjoern Chapuy, Margaret A. Shipp

Blood (2019) 133 (1): 70–80.

https://doi.org/10.1182/blood-2018-08-872465

Published: 2019

Includes: Supplemental data

Journal Articles

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Patricia Gomez-Bougie, Sophie Maiga, Benoît Tessoulin, Jessie Bourcier, Antoine Bonnet, Manuel S. Rodriguez, Steven Le Gouill, Cyrille Touzeau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot

Blood (2018) 132 (25): 2656–2669.

https://doi.org/10.1182/blood-2018-03-836718

Published: 2018

Includes: Supplemental data

Journal Articles

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

Binu K Sasi, PhD, Sven Turkalj, BS, Hilal Kalkan, BS, Fabiola Porro, MS, Engin Bojnik, PhD, Beata Pyrzynska, PhD, Abdessamad Zerrouqi, PhD, Malgorzata Bobrowicz, PhD, Magdalena Winiarska, PhD, Valdemar Priebe, MS, Francesco Bertoni, MD, Larry Mansouri, PhD, Richard Rosenquist, MD PhD, Dimitar G Efremov, MD PhD

Blood (2018) 132 (Supplement 1): 2860.

https://doi.org/10.1182/blood-2018-99-118120

Published: 2018

Journal Articles

Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Luciano J Costa, MD PhD, Edward A. Stadtmauer, MD FACP, Gareth Morgan, MD, Gregory Monohan, MD, Tibor Kovacsovics, MD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Mehrdad Mobasher, MD MPH, Kevin J. Freise, PhD, Jeremy A. Ross, PhD, John Pesko, PhD, Wijith Munasinghe, PhD, Saketh Gudipati, MD, Sarah Mudd, PhD, Orlando Bueno, MD PhD, Shaji K. Kumar, MD

Blood (2018) 132 (Supplement 1): 303.

https://doi.org/10.1182/blood-2018-99-117026

Published: 2018

NARROW

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death

Requirement for antiapoptotic MCL-1 during early erythropoiesis

Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA)

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma

Does Venetoclax Cause Vitiligo?

All-Trans Retinoic Acid Enhances the Anti-Leukemia Effect of Venetoclax on Acute Myeloid Leukemia Cells

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

Mechanisms of Deregulation of Apoptosis in Myeloma

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Functional profiling to improve therapy in TCL

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only